{"id":"W2094188569","doi":"10.1038/bjc.2011.182","title":"Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy","year":2011,"lang":"en","type":"article","venue":"British Journal of Cancer","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Juravinski Cancer Centre; Hamilton Health Sciences; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Cetuximab; Pharmacodynamics; Pharmacokinetics; Internal medicine; Nausea; Response Evaluation Criteria in Solid Tumors; Adverse effect; Oncology; Gastroenterology; Cancer; Pharmacology; Colorectal cancer; Chemotherapy; Phases of clinical research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001275262,0.0009591855,0.001827117,0.0003686893,0.0002865564,0.0007103989,0.0008975707,0.0007875961,0.002477927],"category_scores_gemma":[0.001017553,0.0004967277,0.0007780986,0.0004249498,0.0005652916,0.0005498145,0.0003081817,0.003044889,0.0006806355],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007573972,"about_ca_system_score_gemma":0.0008528564,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003899253,"about_ca_topic_score_gemma":0.0009982698,"domain_scores_codex":[0.9995109,0.0002453321,0.00002202536,0.00007054576,0.00006363245,0.00008752475],"domain_scores_gemma":[0.9993411,0.0001056422,0.000204591,0.00007885815,0.00004300879,0.0002269124],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3607379,0.1200591,0.02146337,0.0009844186,0.0030124,0.0006660325,0.0006942726,0.009526314,0.2854191,0.0003755639,0.005427447,0.1916341],"study_design_scores_gemma":[0.2587678,0.6762613,0.03505746,0.00003775777,0.0006372103,0.001184314,0.00008653753,0.003845166,0.01923315,0.0001943145,0.004648937,0.00004606013],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963695,0.0008456209,0.0006506609,0.000161316,0.00003606257,0.0006953779,0.0002148008,0.0000915709,0.0009351061],"genre_scores_gemma":[0.9943268,0.0005195868,0.001981404,0.0003665421,0.00005513126,0.0008607231,0.0009462908,0.00002962887,0.0009140074],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002477927,"threshold_uncertainty_score":0.008289456,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01573615130210611,"score_gpt":0.2929622665639344,"score_spread":0.2772261152618283,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}